Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 30; no. 5; pp. e64 - e68
Main Authors Subbiah, Vivek, Slopis, John, Hong, David S, Ketonen, Leena M, Hamilton, Jackson, McCutcheon, Ian E, Kurzrock, Razelle
Format Journal Article
LanguageEnglish
Published United States American Society of Clinical Oncology 10.02.2012
Subjects
Adolescent
Adult
Angiogenesis Inhibitors - therapeutic use
Antibodies, Monoclonal, Humanized - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Benzenesulfonates - administration & dosage
Bevacizumab
Child
Child, Preschool
Diagnosis in Oncology
Drug Synergism
Erlotinib Hydrochloride
Faze
Female
Humans
Indoles - administration & dosage
Male
Molecular Targeted Therapy - methods
Neurofibromatosis 2 - drug therapy
Neurofibromatosis 2 - genetics
Niacinamide - analogs & derivatives
Phenylurea Compounds
Pyridines - administration & dosage
Pyrroles - administration & dosage
Quinazolines - administration & dosage
Rare
Sirolimus - administration & dosage
Sirolimus - analogs & derivatives
TOR Serine-Threonine Kinases - antagonists & inhibitors
Treatment Outcome
Valproic Acid - administration & dosage
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Young Adult
Online AccessGet full text

Cover

More Information
ISSN:0732-183X
1527-7755
DOI:10.1200/JCO.2011.38.2614